ABVC Stock - ABVC BioPharma, Inc.
Unlock GoAI Insights for ABVC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $509,589 | $152,430 | $969,783 | $355,797 | $483,045 |
| Gross Profit | $508,826 | $-149,607 | $683,368 | $350,711 | $464,329 |
| Gross Margin | 99.9% | -98.1% | 70.5% | 98.6% | 96.1% |
| Operating Income | $-4,705,242 | $-6,766,734 | $-15,114,412 | $-11,705,968 | $-8,505,776 |
| Net Income | $-4,902,878 | $-7,788,050 | $-16,423,239 | $-12,838,813 | $-9,791,164 |
| Net Margin | -962.1% | -5109.3% | -1693.5% | -3608.5% | -2027.0% |
| EPS | $-0.42 | $-1.80 | $-5.20 | $-5.10 | $-5.00 |
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
Visit WebsiteEarnings History & Surprises
ABVCEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 28, 2026 | — | — | — | — |
Q4 2025 | Oct 31, 2025 | — | $-0.05 | — | — |
Q3 2025 | Aug 13, 2025 | — | $-0.13 | — | — |
Q2 2025 | Apr 30, 2025 | — | $-0.06 | — | — |
Q2 2025 | Apr 15, 2025 | — | $0.04 | — | — |
Q4 2024 | Nov 14, 2024 | — | $-0.02 | — | — |
Q3 2024 | Aug 14, 2024 | — | $-0.09 | — | — |
Q2 2024 | May 17, 2024 | — | $-0.40 | — | — |
Q1 2024 | Mar 13, 2024 | $-0.50 | $-0.35 | +30.0% | ✓ BEAT |
Q4 2023 | Nov 15, 2023 | $-0.40 | $-0.82 | -105.0% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $-0.60 | $-0.68 | -13.3% | ✗ MISS |
Q2 2023 | May 15, 2023 | $-0.50 | $-0.60 | -20.0% | ✗ MISS |
Q1 2023 | Mar 31, 2023 | $-1.90 | $-1.50 | +21.1% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-2.00 | $-1.10 | +45.0% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $-2.00 | $-0.60 | +70.0% | ✓ BEAT |
Q2 2022 | May 16, 2022 | — | $-2.00 | — | — |
Q1 2022 | Mar 31, 2022 | $-0.04 | $-0.31 | -675.0% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | $-0.40 | $-0.70 | -75.0% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-0.04 | $-0.81 | -1918.3% | ✗ MISS |
Q2 2021 | May 10, 2021 | — | $-0.46 | — | — |
Frequently Asked Questions about ABVC
What is ABVC's current stock price?
What is the analyst price target for ABVC?
What sector is ABVC BioPharma, Inc. in?
What is ABVC's market cap?
Does ABVC pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ABVC for comparison